Alcobra Company Profile (NASDAQ:ADHD)

About Alcobra (NASDAQ:ADHD)

Alcobra logoAlcobra Ltd is a development-stage biopharmaceutical company. The Company is focused on development and commercialization of its lead product candidates, including MDX and ADAIR. MDX is a oral drug, for the treatment of ADHD and other cognitive disorders, including Fragile X. MDX is a combined rapid onset ER formulation of the chemical pyridoxine pyroglutamate, which is more commonly known as metadoxine. MDX consists of a single bi-layer oral tablet, which includes both a rapid onset release metadoxine formulation and a slow release metadoxine formulation together providing the desired dual release profile. The new extended-release formulation prolongs the human plasma levels of metadoxine for up to 12 hours, which results in enhanced efficacy benefits. ADAIR is an oral, semi-solid, liquid-filled, hard gelatin capsule of an abuse-deterrent IR formulation of dextroamphetamine sulfate, which is manufactured as 10 mg capsules.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ADHD
  • CUSIP: N/A
  • Web:
  • Market Cap: $43.82 million
  • Outstanding Shares: 27,562,000
Average Prices:
  • 50 Day Moving Avg: $1.12
  • 200 Day Moving Avg: $1.12
  • 52 Week Range: $0.83 - $2.58
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.34
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.48 per share
  • Price / Book: 1.07
  • EBITDA: ($21,410,000.00)
  • Return on Equity: -45.34%
  • Return on Assets: -42.69%
  • Current Ratio: 25.53%
  • Quick Ratio: 25.53%
  • Average Volume: 923,712 shs.
  • Beta: 1.49
  • Short Ratio: 13.65

Frequently Asked Questions for Alcobra (NASDAQ:ADHD)

What is Alcobra's stock symbol?

Alcobra trades on the NASDAQ under the ticker symbol "ADHD."

How were Alcobra's earnings last quarter?

Alcobra Ltd. (NASDAQ:ADHD) posted its quarterly earnings results on Friday, August, 11th. The company reported ($0.13) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.02. View Alcobra's Earnings History.

When will Alcobra make its next earnings announcement?

Alcobra is scheduled to release their next quarterly earnings announcement on Wednesday, November, 15th 2017. View Earnings Estimates for Alcobra.

Where is Alcobra's stock going? Where will Alcobra's stock price be in 2017?

8 analysts have issued 1 year price objectives for Alcobra's stock. Their predictions range from $1.00 to $2.00. On average, they expect Alcobra's share price to reach $1.61 in the next year. View Analyst Ratings for Alcobra.

What are analysts saying about Alcobra stock?

Here are some recent quotes from research analysts about Alcobra stock:

  • 1. According to Zacks Investment Research, "Alcobra Ltd. is a biopharmaceutical company. It focuses on the development and commercialization of drugs to treat attention deficit hyperactivity disorder. Alcobra Ltd. is headquartered in Tel Aviv, Israel. " (10/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Development of new drugs carries a high failure rate, either because the drug in question fails to show efficacy or significant safety issues arise during the clinical trial process. In addition, regulatory authorities such as the Food & Drug Administration (FDA) may delay the approval process or reject Alcobra’s clinical findings." (4/13/2017)
  • 3. Piper Jaffray Companies analysts commented, "We're not particularly surprised by this outcome as the truncated dataset greatly reduced the power of this trial to demonstrate a significant impact on the CAARS. Alcobra now plans to use its ~$50M in cash to execute on a new business plan, the details of which should become available during 1Q17. We expect this could involve development of MDX in ex-US markets, or of new candidates from the company's internal pipeline or in-licensing efforts. Given the prolonged timelines to next clinical data and first revenues, as well as increased execution risk we see for this team, we are reducing our PT from $3 to $1.50, or roughly equivalent to cash/share. In advance of more details on a plan forward, we reiterate N." (1/17/2017)

Who are some of Alcobra's key competitors?

Who are Alcobra's key executives?

Alcobra's management team includes the folowing people:

  • Yaron Daniely, Chairman of the Board
  • David C. Baker, Interim Chief Executive Officer and Chief Commercial Officer
  • Tomer Berkovitz, Chief Financial Officer
  • Hagit Marchaim Ph.D., Senior Vice President - Regulatory Affairs
  • Hanna Ron, Senior Vice President of Chemistry, Manufacturing and Control
  • Oded Edri, Vice President - Finance
  • Johanna Schumann, Vice President - Preclinical Development
  • Jonathan Rubin M.D., Chief Medical Officer
  • Daniel E. Geffken CPA, Director
  • Aharon Schwartz, Director

How do I buy Alcobra stock?

Shares of Alcobra can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alcobra's stock price today?

One share of Alcobra stock can currently be purchased for approximately $1.59.

MarketBeat Community Rating for Alcobra (NASDAQ ADHD)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  356
MarketBeat's community ratings are surveys of what our community members think about Alcobra and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alcobra (NASDAQ:ADHD) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 6 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $1.61 (1.08% upside)
Consensus Price Target History for Alcobra (NASDAQ:ADHD)
Price Target History for Alcobra (NASDAQ:ADHD)
Analysts' Ratings History for Alcobra (NASDAQ:ADHD)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017WBB SecuritiesUpgradeHold -> Buy$2.00N/AView Rating Details
9/29/2017Roth CapitalDowngradeBuy -> Neutral$4.00 -> $1.00LowView Rating Details
6/12/2017Jefferies Group LLCReiterated RatingHold$1.25LowView Rating Details
4/13/2017Cantor FitzgeraldReiterated RatingHold$1.00LowView Rating Details
1/17/2017Stifel NicolausSet Price TargetHold$2.00N/AView Rating Details
1/17/2017Oppenheimer Holdings, Inc.Reiterated RatingHoldN/AView Rating Details
1/17/2017Piper Jaffray CompaniesSet Price TargetHold$3.00 -> $2.00N/AView Rating Details
10/28/2016Barclays PLCDowngradeEqual Weight -> Underweight$3.00 -> $2.00N/AView Rating Details
9/1/2016Goldman Sachs Group IncReiterated RatingBuyN/AView Rating Details
6/7/2016Canaccord GenuityInitiated CoverageBuyN/AView Rating Details
(Data available from 10/21/2015 forward)


Earnings History for Alcobra (NASDAQ:ADHD)
Earnings by Quarter for Alcobra (NASDAQ:ADHD)
Earnings History by Quarter for Alcobra (NASDAQ ADHD)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/15/2017($0.11)N/AView Earnings Details
8/11/20176/30/2017($0.15)($0.13)ViewN/AView Earnings Details
5/30/20173/31/2017($0.15)($0.13)ViewN/AView Earnings Details
2/15/201712/31/2016($0.26)($0.22)ViewListenView Earnings Details
11/15/2016Q316($0.27)($0.28)$4.30 million$7.90 millionViewN/AView Earnings Details
8/30/2016Q216($0.22)($0.21)ViewListenView Earnings Details
5/16/2016Q116($0.22)($0.18)ViewListenView Earnings Details
2/17/2016Q415($0.24)($0.20)ViewListenView Earnings Details
11/12/2015Q315($0.31)($0.20)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.24)ViewListenView Earnings Details
5/6/2015Q1 2015($0.31)($0.26)ViewN/AView Earnings Details
2/12/2015Q4($0.57)($0.50)ViewN/AView Earnings Details
11/17/2014Q3 14($0.61)($0.77)ViewN/AView Earnings Details
8/11/2014Q2($0.58)($0.57)ViewListenView Earnings Details
2/13/2014Q413($0.35)($0.45)ViewN/AView Earnings Details
11/7/2013Q313($0.28)ViewN/AView Earnings Details
8/6/2013Q213($0.06)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alcobra (NASDAQ:ADHD)
2017 EPS Consensus Estimate: ($0.71)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.15)($0.20)
Q2 20172($0.23)($0.13)($0.18)
Q3 20172($0.18)($0.14)($0.16)
Q4 20172($0.19)($0.15)($0.17)
(Data provided by Zacks Investment Research)


Dividend History for Alcobra (NASDAQ:ADHD)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alcobra (NASDAQ:ADHD)
No insider trades for this company have been tracked by


Headline Trends for Alcobra (NASDAQ:ADHD)
Latest Headlines for Alcobra (NASDAQ:ADHD)
DateHeadline logoToday's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals - October 20 at 3:40 PM logoArcturus Therapeutics (ADHD) Enters Pact with Johnson & Johnson (JNJ) to Discover and Develop RNA Medicines - October 20 at 1:55 AM logoArcturus Therapeutics (ADHD) Enters Pact with Johnson & Johnson (JNJ) to Discover and Develop RNA Medicines - - October 19 at 8:53 PM logoArcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines - October 19 at 3:52 PM logoAlcobra Ltd (ADHD) Stock Fires Up To The Roof; Here’s Why - October 19 at 3:52 PM logoArcturus Merges With Alcobra - Seeking Alpha - October 15 at 3:22 PM logoAlcobra Ltd. (ADHD) Lowered to "Hold" at Zacks Investment Research - October 11 at 8:28 PM logoAlcobra Ltd. (ADHD) Upgraded to "Buy" at WBB Securities - October 9 at 10:50 PM logoAlcobra Ltd. (ADHD) Given Consensus Rating of "Hold" by Analysts - October 7 at 4:52 AM logoArcturus Therapeutics, Inc. to Present at the Chardan Gene Therapy Conference - October 6 at 3:49 PM logoShould You Be Concerned About Alcobra Ltd’s (ADHD) Risks? - October 6 at 1:25 AM logoAlcobra Ltd. (ADHD) Stock Rating Upgraded by Zacks Investment Research - October 4 at 9:14 PM logoRoth Capital Downgrades Alcobra Ltd. (ADHD) to Neutral - September 29 at 10:56 AM logoAlcobra Ltd. (ADHD) Reports Merger with Arcturus Therapeutics Inc. - - September 29 at 9:56 AM logoAlcobra Ltd. (ADHD) Reports Merger with Arcturus Therapeutics Inc. - September 28 at 3:56 PM logoAlcobra Ltd. and Arcturus Therapeutics, Inc. Agree to Merge - September 27 at 7:33 PM logoAlcobra Is A Net-Net That Could Sell Itself - Seeking Alpha - September 20 at 8:28 PM logoAlcobra Ltd. (ADHD) Receives Consensus Recommendation of "Hold" from Brokerages - September 12 at 4:40 AM logoAlcobra Ltd. (ADHD) Given Consensus Recommendation of "Hold" by Analysts - August 18 at 4:42 AM logoAlcobra Ltd. (NASDAQ:ADHD) Releases Earnings Results, Beats Expectations By $0.02 EPS - August 12 at 10:56 AM logoAlcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update - August 11 at 4:00 PM logoAlcobra reports 2Q loss - August 11 at 4:00 PM logoAlcobra Ltd. (ADHD) Set to Announce Quarterly Earnings on Wednesday - August 9 at 7:00 AM logoNew Strong Buy Stocks for July 26th - July 26 at 8:28 PM logoNew Strong Buy Stocks for July 26th - Nasdaq - July 26 at 3:27 PM logoAlcobra Ltd. (ADHD) Expected to Post Earnings of -$0.13 Per Share - July 25 at 12:26 AM logoAlcobra Ltd. (ADHD) Given Average Recommendation of "Hold" by Analysts - July 24 at 10:54 AM logoBioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session - July 21 at 4:45 PM logoBioLine Rx (BLRX) Catches Eye: Stock Adds 5.2% in Session - July 21 at 4:45 PM logoNew Strong Buy Stocks for July 20th - July 20 at 3:50 PM logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives - June 24 at 1:55 AM logoAlcobra Ltd. (ADHD) to Review of Strategic Alternatives - - June 23 at 8:54 PM
News IconUPDATE 1-Shire wins U.S. approval for long-acting ADHD drug - June 22 at 12:53 PM logoShire wins US approval for long-acting ADHD drug - Nasdaq - June 21 at 3:49 PM logoShire's long-acting ADHD drug wins US approval - Nasdaq - June 20 at 8:52 PM logoAlcobra Ltd. (ADHD) Enters Cooperation Agreement with Brosh ... - - June 13 at 5:40 AM logoAlcobra Ltd. (ADHD) Gains on Rumors of Bid from Regenera - - June 9 at 3:25 PM logoSwiss biotech NLS Pharma's ADHD drug succeeds in mid-stage ... - Nasdaq - May 31 at 3:19 PM logoAlcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update - GlobeNewswire (press release) - May 30 at 10:07 AM logoAlcobra (ADHD) CEO to Step Down, Remain on Board - May 16 at 8:20 PM logoAlcobra (ADHD) CEO to Step Down, Remain on Board - - May 15 at 3:20 PM logoAlcobra Announces Leadership Update - GlobeNewswire (press release) - May 15 at 8:09 AM logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting - May 7 at 3:20 PM logoAlcobra (ADHD) And Brosh Group Reach Agreement to Cancel Extraordinary General Meeting - - May 5 at 3:20 PM logoAlcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders - GlobeNewswire (press release) - April 24 at 3:21 PM logoAlcobra Ltd. (ADHD) Rejects Brosh Capital's Request to Hold Extraordinary General Meeting - April 7 at 3:21 PM logoAlcobra Ltd. (ADHD) Rejects Brosh Capital's Request to Hold ... - - April 7 at 6:30 AM logoResearch Reports Initiation on Biotech Stocks -- Alcobra, Cerus, 22nd Century, and Moleculin Biotech - April 3 at 3:32 PM logoBrosh Capital Requests Extraordinary General Meeting at Alcobra (ADHD), Seeks to Remove Board in Full - - March 18 at 3:18 PM logoAlcobra to Host Investor Forum and Webcast on March 28 in New ... - GlobeNewswire (press release) - March 1 at 3:20 PM



Alcobra (ADHD) Chart for Saturday, October, 21, 2017

This page was last updated on 10/21/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.